LON:4BB

4basebio UK Societas Competitors

GBX 335
+15.00 (+4.69 %)
(As of 04/9/2021 04:43 PM ET)
Add
Compare
Today's Range
315
Now: GBX 335
340
50-Day Range N/A
52-Week Range
175
Now: GBX 335
744
Volume5,316 shs
Average Volume9,567 shs
Market Capitalization£41.26 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

4basebio UK Societas (LON:4BB) Vs. ANIC, MPH, VSN, CIR, VRP, and DEST

Should you be buying 4BB stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to 4basebio UK Societas, including Agronomics (ANIC), Mereo BioPharma Group plc (MPH.L) (MPH), Verseon (VSN), Circassia Group (CIR), Verona Pharma plc (VRP.L) (VRP), and Destiny Pharma (DEST).

4basebio UK Societas (LON:4BB) and Agronomics (LON:ANIC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Earnings and Valuation

This table compares 4basebio UK Societas and Agronomics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio UK SocietasN/AN/AN/AN/AN/A
Agronomics£1.05 million138.47N/AGBX (0.20)-145.00

Analyst Recommendations

This is a breakdown of current recommendations for 4basebio UK Societas and Agronomics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
4basebio UK Societas0000N/A
Agronomics0000N/A

Profitability

This table compares 4basebio UK Societas and Agronomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
4basebio UK SocietasN/AN/AN/A
AgronomicsN/AN/AN/A

Summary

Agronomics beats 4basebio UK Societas on 1 of the 1 factors compared between the two stocks.

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and 4basebio UK Societas (LON:4BB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Mereo BioPharma Group plc (MPH.L) and 4basebio UK Societas' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/AGBX (128)-0.21
4basebio UK SocietasN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Mereo BioPharma Group plc (MPH.L) and 4basebio UK Societas, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mereo BioPharma Group plc (MPH.L)0000N/A
4basebio UK Societas0000N/A

Profitability

This table compares Mereo BioPharma Group plc (MPH.L) and 4basebio UK Societas' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A
4basebio UK SocietasN/AN/AN/A

4basebio UK Societas (LON:4BB) and Verseon (LON:VSN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Earnings and Valuation

This table compares 4basebio UK Societas and Verseon's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio UK SocietasN/AN/AN/AN/AN/A
VerseonN/AN/AN/AGBX (14.30)-5.17

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for 4basebio UK Societas and Verseon, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
4basebio UK Societas0000N/A
Verseon0000N/A

Profitability

This table compares 4basebio UK Societas and Verseon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
4basebio UK SocietasN/AN/AN/A
VerseonN/AN/AN/A

4basebio UK Societas (LON:4BB) and Circassia Group (LON:CIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Earnings and Valuation

This table compares 4basebio UK Societas and Circassia Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio UK SocietasN/AN/AN/AN/AN/A
Circassia Group£23.90 million5.07N/AGBX (8.80)-3.30

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for 4basebio UK Societas and Circassia Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
4basebio UK Societas0000N/A
Circassia Group0000N/A

Profitability

This table compares 4basebio UK Societas and Circassia Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
4basebio UK SocietasN/AN/AN/A
Circassia GroupN/AN/AN/A

Summary

Circassia Group beats 4basebio UK Societas on 1 of the 1 factors compared between the two stocks.

4basebio UK Societas (LON:4BB) and Verona Pharma plc (VRP.L) (LON:VRP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Earnings and Valuation

This table compares 4basebio UK Societas and Verona Pharma plc (VRP.L)'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio UK SocietasN/AN/AN/AN/AN/A
Verona Pharma plc (VRP.L)N/AN/AN/AGBX (32.70)-1.68

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for 4basebio UK Societas and Verona Pharma plc (VRP.L), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
4basebio UK Societas0000N/A
Verona Pharma plc (VRP.L)01002.00

Profitability

This table compares 4basebio UK Societas and Verona Pharma plc (VRP.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
4basebio UK SocietasN/AN/AN/A
Verona Pharma plc (VRP.L)N/AN/AN/A

4basebio UK Societas (LON:4BB) and Destiny Pharma (LON:DEST) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for 4basebio UK Societas and Destiny Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
4basebio UK Societas0000N/A
Destiny Pharma0000N/A

Earnings and Valuation

This table compares 4basebio UK Societas and Destiny Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio UK SocietasN/AN/AN/AN/AN/A
Destiny Pharma£305,906.00332.53N/AGBX (11.50)-14.78

Profitability

This table compares 4basebio UK Societas and Destiny Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
4basebio UK SocietasN/AN/AN/A
Destiny PharmaN/AN/AN/A

Summary

Destiny Pharma beats 4basebio UK Societas on 1 of the 1 factors compared between the two stocks.


4basebio UK Societas Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ANIC
Agronomics
0.5$29.00+3.4%£145.55 million£1.05 million-145.00
Mereo BioPharma Group plc (MPH.L) logo
MPH
Mereo BioPharma Group plc (MPH.L)
0.6$26.50+1.9%£138.87 millionN/A-0.21Gap Up
VSN
Verseon
0.5$74.00+2.0%£127.41 millionN/A-5.17Gap Down
Circassia Group logo
CIR
Circassia Group
0.9$29.00+2.6%£121.12 million£23.90 million-3.30Gap Up
Verona Pharma plc (VRP.L) logo
VRP
Verona Pharma plc (VRP.L)
0.5$55.00+5.5%£107.74 millionN/A-1.68Gap Down
Destiny Pharma logo
DEST
Destiny Pharma
0.5$170.00+6.5%£101.72 million£305,906.00-14.78
SBTX
SkinBioTherapeutics
0.4$60.50+2.5%£94.85 millionN/A-60.50Gap Up
C4XD
C4X Discovery
0.6$40.00+0.0%£90.54 million£7.06 million-4.94
ETX
e-therapeutics
0.4$20.70+2.2%£87.10 million£305,000.00-20.70Gap Up
OBD
Oxford BioDynamics
0.5$91.00+2.2%£84.23 million£456,000.00-19.36Gap Up
ReNeuron Group logo
RENE
ReNeuron Group
0.6$133.00+9.0%£75.62 million£112,000.00-2.90Gap Up
OKYO
OKYO Pharma
0.5$7.65+0.0%£51.47 millionN/A-76.50
Tissue Regenix Group logo
TRX
Tissue Regenix Group
0.5$0.67+1.5%£47.12 million£13.05 million-1.68
OptiBiotix Health logo
OPTI
OptiBiotix Health
0.4$52.00+4.8%£45.73 million£687,584.00-22.61
HVO
Hvivo
0.5$16.50+5.3%£43.95 million£12.09 million-0.83
FAB
Fusion Antibodies
0.5$151.00+7.9%£39.18 million£4.05 million-50.33High Trading Volume
RUA
Rua Life Sciences
0.0$155.00+3.2%£34.39 million£835,000.00-18.90
HEMO
Hemogenyx Pharmaceuticals
0.4$7.50+0.0%£34.09 millionN/A-18.75
IXICO logo
IXI
IXICO
1.0$70.50+3.5%£33.82 million£9.53 million35.25High Trading Volume
COS
Collagen Solutions plc (COS.L)
0.6$6.63+0.0%£28.43 million£4.01 million-8.28
ImmuPharma logo
IMM
ImmuPharma
0.6$10.06+1.5%£25.16 million£128,395.00-3.35Gap Down
AOR
AorTech International
0.5$123.50+2.4%£21.85 million£539,000.00-33.38
Midatech Pharma logo
MTPH
Midatech Pharma
0.7$31.00+0.0%£19.65 million£390,000.00-0.33
NFX
Nuformix
0.5$2.55+0.0%£15.09 million£195,550.00-12.75
ValiRx logo
VAL
ValiRx
0.7$20.75+0.0%£13.50 millionN/A-1.15
RLM
Realm Therapeutics
0.7$11.50+0.0%£13.41 million£501,919.00-0.66
OVB
Ovoca Bio
0.7$11.50+0.0%£10.17 millionN/A-2.30
NSCI
NetScientific
0.5$66.50+3.0%£9.99 million£394,000.00-22.93High Trading Volume
Horizon Discovery Group plc (HZD.L) logo
HZD
Horizon Discovery Group plc (HZD.L)
1.3$184.50+97.3%£8.16 million£54.63 million-33.55Gap Down
PYC
Physiomics
0.4$7.05+5.0%£6.86 million£884,649.00-70.50
Motif Bio logo
MTFB
Motif Bio
0.6$0.50+0.0%£3.28 millionN/A-0.18News Coverage
SALV
SalvaRx Group
0.8$4.50+0.0%£1.65 million£64.50 million0.03Gap Down
PEBI
Port Erin Biopharma Investments
0.5$4.50+100.0%£1.04 million£28,300.00-6.43Gap Down
Abzena logo
ABZA
Abzena
0.6$15.75+0.0%£0.00N/A0.00
Vernalis logo
VER
Vernalis
0.7$6.17+0.0%£0.00N/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.